Surface Oncology, Inc. Common Stock
SURF
SURF was delisted on the 7th of September, 2023.
61 hedge funds and large institutions have $16.9M invested in Surface Oncology, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 7 increasing their positions, 14 reducing their positions, and 23 closing their positions.
171% more call options, than puts
Call options by funds: $46K | Put options by funds: $17K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
10% less capital invested
Capital invested by funds: $18.8M → $16.9M (-$1.83M)
14% less funds holding
Funds holding: 71 → 61 (-10)
43% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 23
50% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$3.49M |
| 2 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
+$560K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$195K |
| 4 |
BMCM
Black Maple Capital Management
Milwaukee,
Wisconsin
|
+$190K |
| 5 |
BFM
Boothbay Fund Management
New York
|
+$32.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$2.91M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$2.15M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$908K |
| 4 |
Citigroup
New York
|
-$719K |
| 5 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$698K |
SURF Hedge Fund Activity: Q2 2023 in Review
61 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Surface Oncology, Inc. Common Stock (SURF) for Q2 2023, worth a combined $16.9M — down 9.8% from $18.8M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of SURF and 13 opened new positions — a net loss of 10 holders — while 14 trimmed existing stakes and 7 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $3.49M. The largest seller was ARK Investment Management, cutting an estimated $2.91M.
- 61 institutional investors held Surface Oncology, Inc. Common Stock (SURF) as of Q2 2023, down from 71 in Q1 2023.
- Funds reported $16.9M of Surface Oncology, Inc. Common Stock stock for Q2 2023, down 9.8% quarter-over-quarter.
- 13 funds opened new Surface Oncology, Inc. Common Stock positions in Q2 2023 and 23 closed out, a net change of -10 holders.
- The largest Surface Oncology, Inc. Common Stock buyer in Q2 2023 was Armistice Capital, an estimated $3.49M added.
- The largest Surface Oncology, Inc. Common Stock seller in Q2 2023 was ARK Investment Management, an estimated $2.91M sold.
Based on aggregated 13F filings for Q2 2023.